Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Hassold, Nicole ^a   Seystahl, Katharina ^a   Kempf, Kristina ^a   Urlaub, Doris ^b   Zekl, Michael ^a   Einsele, Hermann ^a   Watzl, Carsten ^b   Wischhusen, Jörg ^a   Seggewiss Bernhardt, Ruth ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

dasatinib; effector functions; NK cells; tyrosine kinase inhibitor; Vav

Indexed keywords

CALCIUM; DASATINIB; GAMMA INTERFERON; GRANZYME B; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA; VAV PROTEIN;

APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG CYTOTOXICITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOCYTE FUNCTION; LYMPHOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CALCIUM; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; NECROSIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, IGG; THIAZOLES;

EID: 84864152607     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27537     Document Type: Article

References (41)

1. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G,. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-63.
2. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035-44.
3. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP,. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415-6.
4. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD,. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37: 256-65.
5. Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M,. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-28.
6. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-405.
7. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH,. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 135-9.
8. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S,. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116: 772-82.
9. Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, Mustjoki S, Seggewiss R,. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25: 1587-97.
10. Bryceson YT, March ME, Ljunggren HG, Long EO,. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 159-66.
11. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD,. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-56.
12. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14: 352-9.
13. Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, Stouffer B,. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 2012; 25: 130-5.
14. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
15. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R,. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484-91.
16. Seong RH, Clayberger, CA, Krensky AM, Parnes JR,. Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene. J Exp Med 1988; 167: 288-99.
17. Figueiredo C, Seltsam A, Blasczyk R,. Permanent silencing of NKG2A expression for cell-based therapeutics. J Mol Med 2009; 87: 199-210.
18. Valiante NM, Rengaraju M, Trinchieri G,. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992; 145: 187-98.
19. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007; 21: 2442-54.
20. Mainiero F, Soriani A, Strippoli R, Jacobelli J, Gismondi A, Piccoli M, Frati L, Santoni A,. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 2000; 12: 7-16.
21. Gõmez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M,. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 2006; 308: 53-67.
22. Alter G, Malenfant JM, Altfeld M,. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22.
23. Jarahian M, Watzl C, Issa Y, Altevogt P, Momburg F,. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer 2007; 120: 2625-34.
24. Chini CC, Boos MD, Dick CJ, Schoon RA, Leibson PJ,. Regulation of p38 mitogen-activated protein kinase during NK cell activation. Eur J Immunol 2000; 30: 2791-8.
25. Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, Trapani JA, Larner AC, Weber MJ, Djeu JY,. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med 1998; 187: 1753-65.
26. Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M,. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-28.
27. Eleme K, Taner SB, Onfelt B, Collinson LM, McCann FE, Chalupny NJ, Cosman D, Hopkins C, Magee AI, Davis DM,. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J Exp Med 2004; 199: 1005-10.
28. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO,. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005; 202: 1001-12.
29. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA,. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
30. Ramoni C, Spadaro F, Menegon M, Podo F,. Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells. J Immunol 2001; 167: 2642-50.
31. Dustin ML, Shaw AS,. Costimulation: building an immunological synapse. Science 1999; 283: 649-50.
32. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109: 4816-24.
33. Jiang K, Zhong B, Gilvary DL, Corliss BC, Vivier E, Hong-Geller E, Wei S, Djeu JY,. Syk regulation of phosphoinositide 3-kinase-dependent NK cell function. J Immunol 2002; 168: 3155-64.
34. Mesecke S, Urlaub D, Busch H, Eils R, Watzl C,. Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal 2011; 4: ra36.
35. Lanier LL,. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74.
36. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, Djeu JY,. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000; 1: 419-25.
37. Djeu JY, Jiang K, Wei S,. A view to a kill: signals triggering cytotoxicity. Clin Cancer Res 2002; 8: 636-40.
38. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL,. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 1999; 96: 5640-4.
39. Grzywacz B, Kataria N, Verneris MR,. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21: 356-9.
40. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-12.
41. Lundqvist A, Berg M, Smith A, Childs RW,. Bortezomib Treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. J Cancer 2011; 2: 383-5.